Significant Rise in Cancer Incidences to Drive Asia-Pacific Monoclonal Antibodies Market

Asia-Pacific monoclonal antibodies market is estimated to grow at a CAGR of 8.9% during the forecast period. Rising cancer incidences is the major factor in accelerating market growth. As per the World Health Organization (WHO), there were 4.3 million new cancer incidences reported in the country. Of these, lung (18.1%), colorectum (12.2%), stomach (10.6%), liver (9.2%), breast (8.6%), and other cancers (41.4%) of all new cancer cases in the country. Rising awareness regarding early detection of cancer has been witnessed in the country, which is supporting the increasing demand for novel cancer therapies. Monoclonal antibodies are laboratory-engineered molecules designed to attack particular features that are found on cancer cells. These antibodies are designed to discover specific proteins on cancer cells that are associated with the growth of those cells. These therapies may also be utilized to deliver radiation or chemotherapy directly to cancer cells. Monoclonal antibody drugs can function in several ways, including blocking cell growth and immune system inhibitors, flagging cancer cells, delivering chemotherapy and radiation treatment, directly attacking cancer cells, and others. 

Browse the full report description of "Asia-Pacific Monoclonal Antibodies Market Size, Share & Trends Analysis Report, By Source (Murine, Chimeric, Human, and Humanized), By Application (Cancer, Infectious Diseases, Auto-Immune Diseases, Inflammatory Diseases, and Others) and Forecast, 2020-2026" at https://www.omrglobal.com/industry-reports/asia-pacific-monoclonal-antibodies-market

Scope of the Asia-Pacific Monoclonal Antibodies Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Source and Application
• Regions Covered- China, India, Japan, and Rest of Asia-Pacific
• Competitive Landscape- Biocon Ltd., Amgen Inc., F. Hoffman La-Roche AG, Pfizer Inc., and Mylan N.V.

Recent Strategic Initiatives in the Asia-Pacific Monoclonal Antibodies Market

• In July 2020, Cadila Pharmaceuticals Ltd. declared the introduction of biosimilar Rituximab in India. It is indicated for the treatment of rheumatoid arthritis and blood cancer launched within the brand name Ritucad. It is used to treat Non-Hodgkin’s lymphoma (a type of blood-related cancer). According to the company, over 28,000 new cases of Lymphoma are reported each year in India. This launch will increase the accessibility of cancer treatment in the country. 
• In October 2019, Amgen declared collaboration with BeiGene that will further widen Amgen's plans to enhance its oncology presence in China. Under the agreement, BeiGene will commercialize BLINCYTO (blinatumomab), XGEVA (denosumab), and KYPROLIS (carfilzomib) in China. Additionally, this acquisition will also support Amgen for the commercialization of its non-oncology product portfolio in China. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID forecast

o Most affected segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Asia-Pacific Monoclonal Antibodies Market-Segmentation

By Source

• Murine
• Chimeric
• Human
• Humanized

By Application

• Cancer
• Infectious Diseases
• Auto-Immune Diseases
• Inflammatory Diseases
• Others

Asia-Pacific Monoclonal Antibodies Market– Segment by Country

• China
• Japan
• India
• Rest of Asia-Pacific